Service Hotline: 400-826- 0806

News center


[Partner] Tian-Guang Cheng Jianhua real promise in hand to tackle cell lymphoma

Date: 2019-09-10
Views: 15

Note: Beijing Tian-Guang real Biotechnology Co., Ltd. of Paradise Valley invested enterprises

Recently, Paradise Valley Medical Health Division of the portfolio companies - Beijing Tian-Guang real Biotechnology Co., Ltd. (hereinafter referred to as 'wide-day reality') and Beijing Connaught Cheng Jian Hua Pharmaceutical Co., Ltd. (hereinafter referred to as 'Snow Cheng Jian Hua' ) jointly announced that they won the State Drug Administration Center for Drug Evaluation (CDE) clinical trials implied license to Connaught Jian Hua novel selective inhibitor of BTK ICP-022 (Orelabrutinib) Tian Guang real joint recombinant humanized type II CD20 monoclonal antibody injection MIL62 treatment of relapsed, refractory CD20 + B cell lymphoma.

ICP-022 (Orelabrutinib) and MIL62 injection alone show a good safety and efficacy in the clinical I / II trials, expected recurrent, refractory B-cell lymphoma by providing a better combination of mechanisms of action treatment options.

It is understood that, until now, has been five days of extensive real-drug antibodies into the clinic. Speaking so fast and efficient research and development progress, Tian Guang real responsible person admits, helped in the fight against Ebola drug development, academicians and experts to deepen understanding and cooperation, and set up workstations academicians and experts to promote the company antibodies drug development process.

Tian-Guang actual design and function of antibodies is specialized in preclinical and clinical production of antibody drug industrialization and development of high-tech enterprises. Settled after the Beijing Economic and Technological Development, we have developed more than 10 varieties to meet the critical needs of domestic antibodies in patients, to assume a number of major national science and technology projects. Build self-developed innovative antibody and antibody technology platform, the development of clinical indications, covering lymphoma, leukemia, breast cancer, colorectal cancer, stomach cancer, rheumatoid arthritis, ankylosing spondylitis number of innovative antibody drug varieties .

 (Comprehensive self-: Beijing Daily)

Partners: Paradise Valley in March 2019 to invest in Beijing Tian-Guang real Biotechnology Co., Ltd. by PE funds.

News / Related news More
2017 - 12 - 04
Yongquan Forum and Baishaquan · ZUFE Strategic Cooperation Signing Ceremony were held on the afternoon of 3rd December at Baishaquan M&A Block. Yongquan Forum is a major communication and project paring brand created by Baishaquan M&A Block. By hold sharing session and salon or giving speech each month, the forum serves as a communication platform for industry leaders with certai...
2017 - 11 - 30
CAI Gangqing, president and deputy secretary of the Party Committee of Anji Industrial Investment Development Group (IIDG) paid a visit to TTGG with 5 colleagues on the afternoon of 30th November. ZOU Jin, general manager and deputy secretary of the Party Committee of IIDG, FANG Jun, vice-general manager, and other department heads of IIDG attended the discussion. Our managing partner ZHANG Y...
2017 - 11 - 28
Zvi Heifetz, Israeli Ambassador to China, paid a visit to TTGG along with his wife on the evening of 28th November 2017. They were greeted by TTGG’s president YU Baohong. ZHANG Yu and GUO Feng, managing partners of TTGG, LI Xiang, general-manager of Investment Management Department, and other department heads also took part in the meeting.After greeting, YU briefly introduced TTGG’s hist...
2017 - 08 - 14
With the accelerating rhythm of the society, more and more white-collars are feeling stressed under modern work environments. In fact, such stress primarily results from the target-oriented time management. The key factors facilitating their abilities to improve time management efficiency and effectiveness are: how to find the causes of inefficiency, how to distinguish between the important things...
Copyright © 2016 - 2019 Zhejiang Paradise Silicon Valley Asset Management Group Co., Ltd










  • 400-826-0806